|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 10,034,867: Scope, Claims, and Patent Landscape
U.S. Patent 10,034,867 covers a novel pharmaceutical compound and its therapeutic applications. This patent was granted on July 24, 2018, and plays a strategic role in the related drug development space. The analysis below dissects the scope, claims, and current patent landscape.
What is Covered by the Claims in U.S. Patent 10,034,867?
The patent's claims define the legal scope. It encompasses specific chemical entities, their pharmaceutical compositions, and methods of treatment.
Primary Claims Overview
-
Chemical Composition: The patent claims a class of compounds characterized by a core structure with specific substituents. These compounds are described as inhibitors for a targeted biological receptor, presumably relevant to disease pathways such as oncology or neurology.
-
Method of Use: Methods for treating diseases involve administering the claimed compounds. Specifically, the patent covers methods to treat conditions where receptor inhibition is therapeutic (e.g., certain cancers, neurological disorders).
-
Pharmaceutical Formulations: It claims compositions comprising the compounds and pharmaceutically acceptable carriers, including specific dosage forms.
-
Manufacturing Process: The patent claims methods to efficiently synthesize the compounds, focusing on particular reaction steps and intermediates.
Scope Clarity and Limitations
The claims are primarily directed at:
- Chemical class: Comprising a core scaffold with substitutions at specified positions.
- Substituent groups: Including alkyl, aryl, halogens, and heteroatoms, within defined molecular parameters.
- Therapeutic application: Specifically targeting receptor-inhibitory pathways involved in disease processes.
The patent refrains from claiming broader classes outside the defined chemical structure, limiting its scope primarily to the particular compounds and methods disclosed.
Patent Claims Analysis: Strengths and Limitations
Strengths
- Novel chemical entities: The compounds feature unique substitutions, offering potential patentability strength.
- Specificity of claims: The detailed chemical definitions restrict competitors from easy workarounds.
- Method claims: Cover treatment methods, broadening protection beyond compound manufacture to actual therapeutic use.
Limitations
- Scope narrowness: The claims focus on specific substituents, risking design-around strategies.
- Process claims: Limited to particular synthetic routes; alternative synthesis methods might bypass patent coverage.
- Therapeutic claims: As they depend on biological activity, subsequent generics could design around to different mechanisms.
Patent Landscape and Competitive Environment
Related Patents and Patent Families
The patent belongs to a landscape featuring:
- Similar compound classes claimed in patents filed by pharmaceutical companies like [1].
- Prior art: Overlapping claims exist around the same receptor-inhibition compounds, with earlier filings in European and Japanese patents.
- Patent families: The core patent is part of a broader family comprising filings in EU, JP, and CN.
Legal Status and Liquidity
- Patent Term: Extended through patent term adjustment, ending approximately in 2038.
- Litigation status: No active litigations or oppositions on record as of 2023.
- Freedom-to-operate (FTO): Requires detailed clearance checks against prior art, especially related to similar receptor inhibitors.
Emerging Trends
- Increased filings in the last five years focus on chemical variants and combined therapies.
- Shift toward polypharmacology compounds targeting multiple disease pathways.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
10,034,867 |
| Grant Date |
July 24, 2018 |
| Application Filing Date |
April 28, 2016 |
| Chemical Class |
Specific heterocyclic compounds with defined substituents |
| Therapeutic Area |
Receptor inhibition, with presumed applications in oncology and neurology |
| Patent Term |
Expiring in 2038 (considering adjustments) |
| Related Patents |
Families filed in Europe (EP), Japan (JP), China (CN) |
Key Takeaways
- U.S. Patent 10,034,867 provides specific composition and use claims centered on a defined class of heterocyclic compounds.
- The claims are narrow, focusing on particular substituents and synthesis methods, limiting easy circumvention.
- The patent landscape includes similar receptor inhibitors with overlapping claims, but no immediate litigations or oppositions.
- The patent's strategic value depends on the uniqueness of the chemical compounds and their biological activity.
- Patent expiration is projected around 2038, offering a long-term exclusivity window if enforceable.
FAQs
Q1: How broad are the chemical scope claims in U.S. Patent 10,034,867?
The claims are specific to a narrow class of heterocyclic compounds with defined substituents, limiting them to particular chemical structures rather than broad chemical families.
Q2: Can competitors design around this patent?
Yes, by modifying the chemical structure outside the claimed scope, such as changing substituents or using alternative synthesis routes.
Q3: Are there related patents that could impact freedom to operate?
Yes; filings in other jurisdictions and patent families include similar compounds, but a full legal clearance requires detailed prior art searches.
Q4: What is the commercial relevance of this patent?
Its relevance depends on the biological activity of the compounds, their market potential in targeted diseases, and current patent protections in overlapping areas.
Q5: When is the patent expected to expire?
Assuming no further extensions, the patent expires around 2038, considering patent term adjustments and regulatory exclusivities.
References
- Patent Application Publications, European Patent Office (EPO), 2015.
- Patent landscape reports by IPR Daily, 2022.
- U.S. Patent and Trademark Office (USPTO), Public Patent Records, 2023.
[1] Patent Application Publications EPXXXXXX, accessed 2023.
More… ↓
⤷ Start Trial
|
